Delivery Order SPE2DB20D2014-SPE2DB26FA19Q
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on October 22, 2025, for Nucynta ER 250 mg tablets (60-count supply). The contract is valued at $1,460.09 with a firm fixed price structure and an ultimate completion date of October 23, 2025. This award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,864.76 for 100 tablets of Nucynta 75 mg on June 2, 2025, with completion scheduled for June 3, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award represents a specific pharmaceutical delivery under DLA's medical supply chain operations, with performance to occur at the vendor's corporate office location in Conshohocken, Pennsylvania. This...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Nucynta 75 mg tablets (100-count units) valued at $30,223.35. This firm fixed-price delivery order, with an ultimate completion date of September 15, 2025, represents a non-competitive award to the pharmaceutical distributor. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical...
- AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 14, 2025, for the supply of Nucynta 50 mg tablets in quantities of 100 units. This competitively awarded, non-set-aside contract carries a ceiling value of $1,961.06 and is structured as a firm fixed-price delivery order with an ultimate completion date of July 15, 2025. The place of performance is identified as Conshohocken, PA, where...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitively-procured delivery order by the Defense Logistics Agency on July 10, 2025, for Nucynta ER 100 mg tablets (60 count). The order, valued at $2,944.08 with a firm fixed price structure, is scheduled for completion by July 11, 2025, and will be performed at the company's Conshohocken facility. This award carries no set-aside designation and represents a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Nucynta 75 mg tablets (100-count units) with a ceiling value of $1,546.83. This firm fixed-price delivery order, which utilizes no set-aside designation, is set to be completed by October 23, 2025, and will be fulfilled from the contractor's Conshohocken, Pennsylvania location. The award represents a child contract under AmerisourceBergen's existing Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order award on October 6, 2025, for Nucynta ER Tabs 100mg with a ceiling value of $5,338.16. This firm fixed price delivery order, with an ultimate completion date of October 7, 2025, was competitively awarded without set-aside provisions to support the Defense Logistics Agency's Medical Supply Chain. The contract represents a continuation of AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,230.11 for Nucynta Tabs 100mg on August 21, 2025. This firm fixed-price contract, which has no set-aside designation, was funded by the Defense Logistics Agency's Medical Supply Chain and will be performed at the awardee's Conshohocken facility, with an ultimate completion date of August 22, 2025. The delivery order represents a short-duration...
- The Defense Logistics Agency awarded a $3,614.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Nucynta ER 100 mg tablets (60-count bottles). This is a non-set-aside contract with an ultimate completion date of September 18, 2025. The place of performance is AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 16, 2025, for the supply of Nucynta 100 mg tablets (100-count units) under a firm fixed-price contract valued at $1,908.20. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX), valued at $999.99 billion and extending through December 2026. The...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB26FA19QDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on October 27, 2025, for Nucynta 75 mg tablets (100 count) with a ceiling value of $2,148.54 under a firm fixed-price contract. This is a non-set-aside award delivered to the place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of October 28, 2025. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider headquartered in Conshohocken, Pennsylvania, is a critical federal medical procurement vendor serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive portfolio of federal contract awards with the DLA, encompassing specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. All reviewed awards demonstrate competitive procurement practices with firm fixed-price delivery orders, reflecting the company's capability to meet federal pharmaceutical supply requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.1k | 10/27/25 |